Clinical trial
Prospective, Multicenter and Observational Registry for the Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm) (Reto 320 Study)
NCT03737565 is registered in ClinicalTrials.gov with Fundación EPIC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, Multicenter and Observational Registry for the Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm) (Reto 320 Study)
- Lead sponsor
- Fundación EPIC
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 17, 2019
- Completion date
- January 2, 2025
- Enrollment
- 350 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.